CareDx, Inc (CDNA)
USD 17.72
(4.6%)
USD 17.72
(4.6%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 223.28 Million USD | 99.22% |
| 2022 | 112.08 Million USD | 11.25% |
| 2021 | 100.74 Million USD | 10.91% |
| 2020 | 90.83 Million USD | 72.24% |
| 2019 | 52.73 Million USD | 51.68% |
| 2018 | 34.76 Million USD | -61.16% |
| 2017 | 89.51 Million USD | 57.14% |
| 2016 | 56.96 Million USD | 117.9% |
| 2015 | 26.14 Million USD | 31.75% |
| 2014 | 19.84 Million USD | -87.64% |
| 2013 | 160.54 Million USD | 2.21% |
| 2012 | 157.07 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 202.1 Million USD | 3.02% |
| 2024 Q3 | 203.73 Million USD | 0.81% |
| 2024 Q1 | 196.18 Million USD | -12.14% |
| 2023 Q1 | 108.19 Million USD | -3.47% |
| 2023 Q3 | 107.04 Million USD | -2.34% |
| 2023 Q2 | 109.6 Million USD | 1.3% |
| 2023 FY | 223.28 Million USD | 99.22% |
| 2023 Q4 | 223.28 Million USD | 108.59% |
| 2022 Q2 | 97.73 Million USD | 9.61% |
| 2022 Q1 | 89.16 Million USD | -11.49% |
| 2022 FY | 112.08 Million USD | 11.25% |
| 2022 Q4 | 112.08 Million USD | 3.94% |
| 2022 Q3 | 107.83 Million USD | 10.33% |
| 2021 Q4 | 100.74 Million USD | 10.68% |
| 2021 Q2 | 77.57 Million USD | 11.33% |
| 2021 Q3 | 91.02 Million USD | 17.34% |
| 2021 FY | 100.74 Million USD | 10.91% |
| 2021 Q1 | 69.67 Million USD | -23.29% |
| 2020 Q2 | 83.97 Million USD | 51.58% |
| 2020 FY | 90.83 Million USD | 72.24% |
| 2020 Q4 | 90.83 Million USD | 6.98% |
| 2020 Q1 | 55.4 Million USD | 5.05% |
| 2020 Q3 | 84.9 Million USD | 1.11% |
| 2019 Q2 | 49.74 Million USD | 54.3% |
| 2019 Q4 | 52.73 Million USD | 11.52% |
| 2019 FY | 52.73 Million USD | 51.68% |
| 2019 Q3 | 47.29 Million USD | -4.93% |
| 2019 Q1 | 32.23 Million USD | -7.28% |
| 2018 Q4 | 34.76 Million USD | -26.11% |
| 2018 Q3 | 47.05 Million USD | -7.6% |
| 2018 Q2 | 50.92 Million USD | 11.78% |
| 2018 Q1 | 45.55 Million USD | -49.11% |
| 2018 FY | 34.76 Million USD | -61.16% |
| 2017 FY | 89.51 Million USD | 57.14% |
| 2017 Q4 | 89.51 Million USD | 18.93% |
| 2017 Q3 | 75.26 Million USD | 14.47% |
| 2017 Q2 | 65.75 Million USD | 0.44% |
| 2017 Q1 | 65.46 Million USD | 14.91% |
| 2016 Q3 | 65.31 Million USD | -3.27% |
| 2016 Q4 | 56.96 Million USD | -12.77% |
| 2016 FY | 56.96 Million USD | 117.9% |
| 2016 Q1 | 28.37 Million USD | 8.53% |
| 2016 Q2 | 67.52 Million USD | 137.96% |
| 2015 Q3 | 25.43 Million USD | 3.44% |
| 2015 Q2 | 24.59 Million USD | 3.29% |
| 2015 FY | 26.14 Million USD | 31.75% |
| 2015 Q1 | 23.81 Million USD | 19.99% |
| 2015 Q4 | 26.14 Million USD | 2.77% |
| 2014 Q4 | 19.84 Million USD | -9.07% |
| 2014 Q3 | 21.82 Million USD | -88.2% |
| 2014 Q2 | 184.9 Million USD | 13.43% |
| 2014 Q1 | 163.01 Million USD | 1.54% |
| 2014 FY | 19.84 Million USD | -87.64% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | 160.54 Million USD | 2.21% |
| 2013 Q4 | 160.54 Million USD | 0.0% |
| 2012 FY | 157.07 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Biodesix, Inc. | 94.51 Million USD | -136.243% |
| Castle Biosciences, Inc. | 86.54 Million USD | -158.01% |
| Exact Sciences Corporation | 3.32 Billion USD | 93.287% |
| IDEXX Laboratories, Inc. | 1.77 Billion USD | 87.423% |
| 23andMe Holding Co. | 206.64 Million USD | -8.052% |
| NeoGenomics, Inc. | 739.69 Million USD | 69.814% |
| Neogen Corporation | 1.44 Billion USD | 84.494% |
| Inotiv, Inc. | 588.04 Million USD | 62.029% |
| Psychemedics Corporation | 6.59 Million USD | -3284.162% |
| RadNet, Inc. | 2.07 Billion USD | 89.231% |
| Star Equity Holdings, Inc. | 21.67 Million USD | -930.159% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -6533.015% |
| Illumina, Inc. | 4.36 Billion USD | 94.886% |
| Aspira Women's Health Inc. | 8.62 Million USD | -2488.235% |
| Prenetics Global Limited | 44.01 Million USD | -407.318% |
| iSpecimen Inc. | 6.07 Million USD | -3573.656% |
| OpGen, Inc. | 13.44 Million USD | -1560.885% |
| T2 Biosystems, Inc. | 62.83 Million USD | -255.366% |
| Standard BioTools Inc. | 159.86 Million USD | -39.672% |
| Neuronetics, Inc. | 81.64 Million USD | -173.499% |
| Precipio, Inc. | 3.67 Million USD | -5980.801% |
| Intelligent Bio Solutions Inc. | 5.59 Million USD | -3890.352% |
| Exagen Inc. | 34.25 Million USD | -551.933% |
| Bionano Genomics, Inc. | 118.24 Million USD | -88.831% |
| Check-Cap Ltd. | 1.33 Million USD | -16688.496% |
| Twist Bioscience Corporation | 152.97 Million USD | -45.967% |
| Guardant Health, Inc. | 1.62 Billion USD | 86.282% |
| BioNexus Gene Lab Corp. | 1.74 Million USD | -12718.287% |
| Natera, Inc. | 691.79 Million USD | 67.724% |
| Fulgent Genetics, Inc. | 139.82 Million USD | -59.693% |
| Sera Prognostics, Inc. | 25.28 Million USD | -783.151% |
| OPKO Health, Inc. | 622.47 Million USD | 64.129% |
| Personalis, Inc. | 95.65 Million USD | -133.422% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -455.081% |
| Applied DNA Sciences, Inc. | 8.77 Million USD | -2443.374% |
| Myriad Genetics, Inc. | 312.9 Million USD | 28.64% |
| ICON Public Limited Company | 7.74 Billion USD | 97.119% |
| Star Equity Holdings, Inc. | 21.67 Million USD | -930.159% |
| MDxHealth SA | 121.92 Million USD | -83.136% |
| Prenetics Global Limited | 44.01 Million USD | -407.318% |
| DarioHealth Corp. | 38.24 Million USD | -483.833% |
| ENDRA Life Sciences Inc. | 1.09 Million USD | -20288.584% |
| Medpace Holdings, Inc. | 1.09 Billion USD | 79.662% |
| Mainz Biomed B.V. | 12.15 Million USD | -1736.272% |
| Trinity Biotech plc | 83.38 Million USD | -167.782% |
| Sotera Health Company | 2.68 Billion USD | 91.689% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -6533.015% |